PMID: 8970248Nov 1, 1996Paper

A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III

Survey of Ophthalmology
J B Serle

Abstract

The safety and ocular hypotensive efficacy of twice-daily administration of brimonidine 0.2% solution or betaxolol 0.25% suspension were compared in subjects with open-angle glaucoma or ocular hypertension. A total of 206 adult patients were enrolled in a prospective, 3-month, multicentered, randomized, double-masked, parallel-group study. Both drugs significantly (p < 0.001) reduced peak and trough intraocular pressure (IOP) at every scheduled follow-up visit over the 3-month study. At peak, the overall mean decrease from baseline IOP was greater (p = 0.004) in the brimonidine-treated group (5.8 mm Hg) than in the betaxolol-treated group (3.8 mm Hg). At trough, the overall mean decrease from baseline (p < 0.001) was 3.9 mm Hg in the brimonidine-treated group and 3.2 mm Hg in the betaxolol-treated group. The IOP-lowering effect of brimonidine was sustained throughout the 3-month study period. Terminations from the study due to lack of efficacy included 2.9% (3/103) of patients in the brimonidine group and 4.2% (4/96) of those in the betaxolol group. The overall incidence of adverse events was similar in both treatment groups, with the only significant (p = 0.027) between-group difference being that ocular blurring was reported ...Continue Reading

References

Mar 1, 1989·Archives of Ophthalmology·J S PulidoC F Blodi
Jul 1, 1988·Archives of Ophthalmology·A L Robin
Dec 1, 1995·Archives of Ophthalmology·C B TorisM E Yablonski

❮ Previous
Next ❯

Citations

Mar 15, 2006·International Ophthalmology·John S CohenLinda J Greff
Apr 3, 2004·American Journal of Ophthalmology·William C StewartJessica N Jenkins
Mar 8, 2000·American Journal of Ophthalmology·A M CarlssonR P LeBlanc
Oct 6, 2000·American Journal of Ophthalmology·D B BylesJ F Salmon
May 20, 1999·American Journal of Ophthalmology·D H ShinK D Nguyen
Jan 22, 2002·Survey of Ophthalmology·Robert L StamperEve J Higginbotham
Sep 3, 2002·Survey of Ophthalmology·Philip F J Hoyng, Yoshi Kitazawa
Nov 1, 1996·Survey of Ophthalmology·J T Wilensky
May 25, 2002·Journal of the American Geriatrics Society·Gary D NovackD William Molloy
May 11, 2002·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Yuh-Fang ChenChuhsing K Hsiao
Feb 19, 2005·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Faruk OztürkSevim Yaman
Jul 1, 2006·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Ho Yeop YeomGong Je Seong
Sep 29, 2007·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Chan Yun KimGong Je Seong
Aug 26, 1998·Australian and New Zealand Journal of Ophthalmology·W E Gillies, A M Brooks
Mar 25, 2008·Therapeutics and Clinical Risk Management·Robert J Noecker
May 8, 2014·Journal of Dermatological Science·David PiwnicaJérôme Aubert
Feb 28, 2002·Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie·Pierre Blondeau, Jacques Armand Rousseau
Feb 26, 2016·Advances in Therapy·Anastasios G P KonstasStefano Miglior
Apr 7, 2010·Expert Opinion on Drug Safety·Mamun Q RahmanDonald M I Montgomery
Aug 25, 2020·Expert Opinion on Pharmacotherapy·Aakriti G ShuklaJonathan S Myers
Oct 23, 2002·Acta Ophthalmologica Scandinavica. Supplement·L TavernitiUNKNOWN Donati
Oct 11, 2001·European Journal of Ophthalmology·R David

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.